Elite Diagnostic Limited (ELITE)
Audited financial statements for the twelve months ended June 30, 2026

Elite Diagnostic Limited (ELITE) reported a 2% increase in revenue totaling $867.30 million for the twelve months ended June 30, 2026, compared to $853.82 million in the corresponding period last year.

Direct costs amounted to $197.33 million (2025: $211.44 million), representing a 7% decrease year over year. Consequently, gross profit increased by 4% to $669.96 million compared to $642.39 million for the twelve months ended June 30, 2025.

Administrative expenses increased by 3% to $413.49 million (2025: $400.90 million), while depreciation increased by 5% from $170.11 million in 2025 to $179.38 million in the period under review. The company also recorded an impairment allowance expense of $818,000 compared to an impairment allowance credit of $1.93 million in the prior year.

As a result, operating profit for the twelve months ended June 30, 2026, amounted to $76.27 million, a 4% increase relative to $73.31 million reported in 2025.

Gain on foreign exchange for the twelve months ended June 30, 2026, amounted to $2.67 million (2025: $2.62 million), while other income was $1.29 million (2025: $133,000). Finance costs totaled $48.31 million, a 23% increase from the corresponding period last year (2025: $39.14 million), reflecting new borrowings drawn to fund capital expansion.

Profit Before Tax for the twelve months ended June 30, 2026, amounted to $31.91 million, a 14% decrease relative to $36.92 million reported in 2025.

Income tax for the twelve months ended June 30, 2026, decreased by 12% to $4.31 million (2025: $4.90 million). As a result, net profit for the year amounted to $27.60 million, a 14% decrease from the $32.02 million reported in 2025.

Consequently, earnings per share (EPS) for the twelve months amounted to $0.08 (2025: $0.09).

Notably, ELITE’s stock price closed on September 28, 2026, at $1.52, with a corresponding P/E ratio of 19.46x, based on the trailing EPS of $0.078.

Balance Sheet Highlights

The company’s assets totalled $1.31 billion (2025: $1.11 billion). The increase in total assets was mainly attributable to a 38% rise in property, plant and equipment to $968.13 million (2025: $701.16 million) following the acquisition of a property for the planned relocation of operations. This was partly offset by a 45% decline in cash and cash equivalents to $124.55 million (2025: $225.55 million).

Shareholders’ equity stood at $570.61 million (2025: $543.01 million), representing a book value per share of $1.61 (2025: $1.54).

Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.

Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.